Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 (opens original article in a new tab)

Crinetics shared positive Phase 2 trial results for atumelnant in treating congenital adrenal hyperplasia and Cushing’s syndrome at ENDO 2026.

• Crinetics presented Phase 2 trial results for atumelnant in congenital adrenal hyperplasia (CAH) at ENDO 2026.
• Atumelnant reduced androgens and allowed lower glucocorticoid doses in CAH patients.
• Phase 1b/2a trial showed atumelnant lowered cortisol and normalized urinary free cortisol in Cushing’s syndrome.